HUTCHMED (China) Limited (HCM.L) LSE

Currency In GBp

Key Executives

Name	Title	Pay	Year Born
Chig Fung Cheng	Acting Chief Executive Officer, Chief Financial Officer & Executive Director	875,356	1967
Weiguo Su	Chief Executive Officer, Chief Scientific Officer & Executive Director (Leave of Absence)	1.32M	1959
Yiling Cui	Executive Vice President & Head of Operations	0	N/A
David Ng	Head of Investor Relations & Capital Strategies	0	N/A
Kin Hung Lee	Senior Vice President of Corporate Management & Communications	0	1977
Selina Zhang	Senior Vice President of Global Human Resources	0	N/A
Xinhui Hu	Executive Vice President & Chief Technical Officer	0	1973
Charles George Rupert Nixon	Group General Counsel	0	1970
Thomas Fu	Senior Vice President of Global Quality	0	N/A
Qingmei Wang	Executive Vice President of Business Development & Strategic Alliances	0	1963

Name

Title

Pay

Year Born

Chig Fung Cheng

Acting Chief Executive Officer, Chief Financial Officer & Executive Director

875,356

1967

Weiguo Su

Chief Executive Officer, Chief Scientific Officer & Executive Director (Leave of Absence)

1.32M

1959

Yiling Cui

Executive Vice President & Head of Operations

N/A

David Ng

Head of Investor Relations & Capital Strategies

N/A

Kin Hung Lee

Senior Vice President of Corporate Management & Communications

1977

Selina Zhang

Senior Vice President of Global Human Resources

N/A

Xinhui Hu

Executive Vice President & Chief Technical Officer

1973

Charles George Rupert Nixon

Group General Counsel

1970

Thomas Fu

Senior Vice President of Global Quality

N/A

Qingmei Wang

Executive Vice President of Business Development & Strategic Alliances

1963

Description

HUTCHMED (China) Limited is a biopharmaceutical company engaged in the research, development, and commercialization of innovative targeted therapies and immunotherapies. Its focus lies in treating cancer and immunological disorders, serving patients both in Hong Kong and globally. The company's operations are divided into Oncology/Immunology and Other Ventures. Among its key assets is Savolitinib, an inhibitor primarily aimed at non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC). Another significant compound, Fruquintinib, targets a range of solid tumors, including CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and other gastrointestinal malignancies. Its extensive pipeline also includes Surufatinib, an inhibitor used in various neuroendocrine tumors (NETs), such as pancreatic and non-pancreatic forms, as well as in biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and additional solid tumors. Further therapeutic candidates include HMPL-523, a spleen tyrosine kinase inhibitor developed for hematological cancers and specific chronic immune conditions, and HMPL-689, which targets isoform PI3Kd. The company is also advancing Tazemetostat, an EZH2 inhibitor currently indicated for certain epithelioid sarcoma and follicular lymphoma patients. Other investigational compounds in its portfolio encompass HMPL-306 for hematological malignancies, gliomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma; HMPL-295 for various solid tumors; and HMPL-653, designed to treat metastatic solid tumors and tenosynovial giant cell tumors. Additionally, it is developing Epitinib (HMPL-813) and Theliatinib (HMPL-309), both representing further inhibitor therapies. HUTCHMED frequently partners with leading pharmaceutical and biotechnology firms, holding collaboration agreements with entities such as AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. Established in 2000, the company rebranded from Hutchison China MediTech Limited to HUTCHMED (China) Limited in May 2021. Its corporate headquarters are situated in Central, Hong Kong.